Your browser doesn't support javascript.
loading
Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Wight, Joel; Hamad, Nada; Campbell, Belinda A; Ku, Matthew; Lee, Kenneth; Rose, Hannah; Armytage, Tasman; Latimer, Maya; Lee, Hui-Peng; Lee, Sze-Ting; Dickinson, Michael; Khor, Richard; Verner, Emma.
Afiliação
  • Wight J; Department of Haematology and Bone Marrow Transplantation, Townsville University Hospital, Townsville, Queensland, Australia.
  • Hamad N; Department of Haematology, Austin Health, Melbourne, Victoria, Australia.
  • Campbell BA; School of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Ku M; School of Medicine, James Cook University, Townsville, Queensland, Australia.
  • Lee K; Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Rose H; School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.
  • Armytage T; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Latimer M; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Lee HP; Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia.
  • Lee ST; Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Dickinson M; Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Khor R; School of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Verner E; Anatomical Pathology Department, NSW Health Pathology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Intern Med J ; 52(9): 1609-1623, 2022 09.
Article em En | MEDLINE | ID: mdl-34532916
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Intern Med J Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália País de publicação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Intern Med J Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália País de publicação: Austrália